Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Petrol Diesel Prices
Char Dham Yatra
Gyanvapi Mosque
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / Getting aggressive calls from powerful people: SII CEO Adar Poonawalla
India

Getting aggressive calls from powerful people: SII CEO Adar Poonawalla

Getting aggressive calls from powerful people: SII CEO Adar Poonawalla
Written by Siddhant Pandey
May 02, 2021, 10:53 am 3 min read
Getting aggressive calls from powerful people: SII CEO Adar Poonawalla

Serum Institute of India CEO Adar Poonawalla has revealed that his decision to fly to London when India is facing a COVID-19 second wave was largely due to the threats he had been facing. The SII is manufacturing doses of the Oxford/AstraZeneca COVID-19 vaccine, labeled 'Covishield'. Facing criticism that the SII is profiteering, Poonawalla also said that Covishield remains the most affordable vaccine.

Details
''Threats' is an understatement'

In an interview with The Times published Saturday, Poonawalla said he has been receiving threatening calls from some of India's most powerful people, who are allegedly pressuring him for vaccine doses. "'Threats' is an understatement," Poonawalla said. "The level of expectation and aggression is really unprecedented. Everyone feels they should get the vaccine. They can't understand why anyone else should get it before them."

Quote
Don't want to guess what they're going to do: Poonawalla

Poonawalla told the publication, "I'm staying here (London) for an extended time because I don't want to go back to that situation. Everything falls on my shoulders but I can't do it alone." "Just because you can't supply the needs of X, Y, or Z you really don't want to guess what they are going to do," he added.

Security
Poonawalla was recently granted 'Y' level security

Poonawalla was granted 'Y' level security by the Indian government earlier this week. The government said that the security was granted in view of the "potential threats" to him. The 'Y' security cover entails a posse of about 4-5 armed commandos of the Central Reserve Police Force (CRPF). The commandos will travel with Poonawalla every time he travels to any part of the country.

Information
Poonawalla plans to expand vaccine manufacturing to other countries

In the interview, Poonawalla indicated that his visit to London is also linked to business plans to expand vaccine manufacturing to countries outside India. When asked if the UK will be one of the production bases outside India, Poonawalla said an announcement is imminent.

Pricing
'Covishield remains most affordable vaccine on planet'

Poonawalla also spoke on the accusations of profiteering as the price of Covishield was recently hiked, calling them "totally incorrect." Covishield continues to be "the most affordable vaccine on the planet," in spite of the price hike, he said. "We have done the best we can without cutting corners or doing anything wrong or profiteering. I'll wait for history to judge," he said.

Pricing
SII faced criticism for differential pricing

After the Centre had allowed state governments and private players to independently procure vaccine doses, the SII announced that Covishield will be available to states at Rs. 400/dose, which was lowered to Rs. 300/dose this week. In the private market, Covishield can be procured at Rs. 600/dose. This drew criticism as the Centre has been procuring doses at a price of Rs. 150 each.

Outbreak
We're gasping for all the help we can get: Poonawalla

On India's COVID-19 situation, Poonawalla said, "I don't think even God could have forecast it was going to get this bad." "We're really gasping for all the help we can get," he said. Notably, India reported a record 3,689 COVID-19 deaths and 3,92,488 new cases on Sunday. The cumulative tally has risen to 1,95,57,457, which includes 33,49,644 active cases and 215,542 deaths.

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Siddhant Pandey
Siddhant Pandey
Twitter
Siddhant Pandey covers national and health news at NewsBytes. He has over five years of experience working as a multimedia journalist covering hard news in New Delhi. He was previously employed with The Indian Express and News World India and has juggled roles as a correspondent, copy editor, and video producer. He holds a Bachelor’s degree in Biotechnology from the Jaypee Institute of Information Technology, Noida.
Latest
Vaccine
Coronavirus
Serum Institute of India
Adar Poonawalla
Related
Latest
ASUS launches gaming monitor that refreshes 500 times per second
ASUS launches gaming monitor that refreshes 500 times per second Technology
Can't revive temple at Qutub Minar, a protected monument: ASI
Can't revive temple at Qutub Minar, a protected monument: ASI India
5 most expensive but weird foods in the world
5 most expensive but weird foods in the world Lifestyle
2nd Test, Day 2: Sri Lanka start well against Bangladesh
2nd Test, Day 2: Sri Lanka start well against Bangladesh Sports
Rajeev Ravi's 'Kuttavum Shikshayum,' 'Thuramukham' book back-to-back release dates
Rajeev Ravi's 'Kuttavum Shikshayum,' 'Thuramukham' book back-to-back release dates Entertainment
Vaccine
COVID-19: India logs 2,487 fresh cases, 13 more fatalities
COVID-19: India logs 2,487 fresh cases, 13 more fatalities India
COVID-19: India logs 2,858 fresh cases, 11 more fatalities
COVID-19: India logs 2,858 fresh cases, 11 more fatalities India
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon India
India inching closer to launching its first dengue vaccine
India inching closer to launching its first dengue vaccine India
National Vaccination Day 2022: Know theme, history, significance
National Vaccination Day 2022: Know theme, history, significance Lifestyle
More News
Coronavirus
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
COVID-19 vaccine precautionary dose available for 18+ from April 10
COVID-19 vaccine precautionary dose available for 18+ from April 10 India
COVID-19 survivors at risk of developing serious blood clots: Study
COVID-19 survivors at risk of developing serious blood clots: Study Technology
COVID-19: India reports 1,660 new cases, 4,100 more deaths
COVID-19: India reports 1,660 new cases, 4,100 more deaths India
More News
Serum Institute of India
COVID-19 vaccine precautionary dose service charge capped at Rs. 150
COVID-19 vaccine precautionary dose service charge capped at Rs. 150 India
DCGI approves emergency use of Covovax in children above 12
DCGI approves emergency use of Covovax in children above 12 India
Govt panel okays phase-3 trials of Covovax as booster dose
Govt panel okays phase-3 trials of Covovax as booster dose India
SII to launch COVID-19 vaccine for children in 6 months
SII to launch COVID-19 vaccine for children in 6 months India
COVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective
COVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective Technology
More News
Adar Poonawalla
EU body says it didn't receive application for Covishield approval
EU body says it didn't receive application for Covishield approval India
Reports claiming fresh COVID-19 vaccine orders not placed baseless: Government
Reports claiming fresh COVID-19 vaccine orders not placed baseless: Government India
Covishield price reduced to Rs. 300 for states: Adar Poonawalla
Covishield price reduced to Rs. 300 for states: Adar Poonawalla India
COVID-19 vaccine production hit as US, Europe obstruct raw material
COVID-19 vaccine production hit as US, Europe obstruct raw material World
AstraZeneca serves legal notice to Serum Institute over vaccine delays
AstraZeneca serves legal notice to Serum Institute over vaccine delays World
More News
Related
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla India
'Not received Covishield approval request,' says EU body amid concerns
'Not received Covishield approval request,' says EU body amid concerns India
Serum to begin Covovax trials on children in July
Serum to begin Covovax trials on children in July India
Covovax India launch by September; trial for kids soon: SII
Covovax India launch by September; trial for kids soon: SII India
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022